In the first part of an exclusive two-part interview, Samsung Bioepis’ development division leader Kyung-Ah Kim and Biogen’s global head of biosimilars Ian Henshaw discuss how the firms are aiming to capitalize...
 

The EU's medical device regulators have joined forces to remind consumer health firms of the rules which must be followed when marketing a nasal spray offering protection from viruses, such as influenza and SARS-CoV-2. 

Amgen’s latest deal shows the biotech major’s need to replenish its portfolios and also the cool heads required when negotiations get heated.

The French firm is searching for a US partner with strong foundations in the hospital sector after securing EU and China deals for its complicated...

The development of oncolytic virus therapy has gained momentum over the past decade, due to its relatively safe mode of action and potential to enhance existing treatment options.
 

Investors at the Advanced Therapies Europe conference in London struck a bullish note on the state of the market and offered up advice for cell and gene developers from fundraising...
 

A compilation of the differences and similarities in regulatory requirements for decentralized trials across the EU member states could help sponsors better understand the nuances per country.
 

Increasing scrutiny is being placed on trial sponsors and regulators to improve trial data reporting. Researchers complain that, without access to specific data, results cannot be easily duplicated, which inhibits greater...